A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

Inclusion Criteria Patients must have: * HIV infection. * Advanced Kaposi's sarcoma. Prior Medication: Allowed: * Prior intralesional vinblastine. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Acute intercurrent infection other than genital herpes. * Uncompensated cardiovascular, hepatic, renal, or pulmonary disease unrelated to Kaposi's sarcoma. * Symptomatic peripheral neuropathy. * Any condition that compromises ability to give informed consent or complete the study. Concurrent Medication: Excluded: * Concurrent ganciclovir. Patients with the following prior conditions are excluded: * Symptomatic AIDS-defining opportunistic infection within 2 weeks of entry. * History of malignancy other than Kaposi's sarcoma, basal cell carcinoma, or carcinoma in situ of the cervix. Prior Medication: Excluded: * Prior systemic chemotherapy. * Intralesional therapies within 7 days prior to study entry. * Growth factors (G-CSF or GM-CSF), immune modifiers, or investigational agents within 14 days prior to study entry. * Interferon preparations (alpha or beta) within 28 days prior to study entry. Prior Treatment: Excluded within 7 days prior to study entry: * Radiation. * Local therapies (e.g., cryotherapy).